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DURING FETAL LIFE, pulmonary vascular resistance is very high, thereby allowing only a small percentage of the total cardiac output to flow through the lungs (14, 16) . Pulmonary vascular adaptation following birth is associated with alveolar expansion, pulmonary vasodilatation, and flow of the total cardiac output through the lungs, thus allowing for adequate gas exchange (9) . Matching of perfusion to ventilation in the lung is acutely controlled by the hypoxic pulmonary vasoconstriction response (7) . The mechanisms responsible for the control and modulation of pulmonary vascular tone are highly complex and remain poorly understood. It is clear that locally produced humoral factors with either dilator (nitric oxide, prostacyclin, and adenosine) or constrictor (thromboxane, endothelin, isoprostanes) properties are involved in the process (8) , although much remains to be understood about their cellular sources and precise roles during the fetal-newborn transition.
The possibility of involvement of the bronchi in the control of pulmonary arterial tone has only received limited attention. Cross talk between the bronchi and arteries of the lung might be reasonably expected to occur, given their common developmental origin and close anatomical proximity.
Flavahan et al. (5) were the first to report on the existence of a bronchial epithelium-derived factor capable of relaxing airway smooth muscle. Subsequently, Fernandes et al. (4) demonstrated that a tracheal epithelium-derived factor was capable of relaxing aortic smooth muscle when the tissues were coaxially mounted in vitro. More recently, Prazma et al. (12) reported that this airway epithelium-derived relaxant factor was capable of modulating the tracheal vascular tone in vivo in the anesthetized rat. However, the potential role of this airway epithelium-derived relaxant factor on the control of pulmonary vascular tone has received little attention.
In studies on pulmonary arterial reactivity in newborn rats, we have recently reported the presence of a bronchial epithelium-derived relaxing factor or factors (BrEpRF) that reduced pulmonary artery force generation, independently of the endothelium (2). The converse was not true, in that bronchial force generation was not affected when studied in the presence of the adjacent pulmonary artery. Given the above observations in the newborn, we reasoned that the BrEpRF might have physiological significance in the control of pulmonary vascular tone during the transition from fetal to postnatal life. We therefore hypothesized that the release and/or activity of this factor would be suppressed in the fetus and would be induced by increased oxygen tension. We also studied the methacholine response of fetal and newborn rat pulmonary arteries with their bronchi attached to evaluate whether BrEpRF release and/or activation could be stimulated pharmacologically. As described herein, we found that the BrEpRF was not active in fetal vessels and was suppressed by hypoxia in newborn vessels.
METHODS
Materials. U-46619 was obtained from Cayman Chemical (Ann Arbor, MI). All other chemicals were obtained from Sigma Chemical (Oakville, ON, Canada) and dissolved in Krebs-Henseleit buffer except for wortmannin, which was first dissolved in DMSO (10 Ϫ2 M) and subsequently in Krebs-Henseleit buffer.
Institutional review. All procedures involving animals were conducted according to criteria established by the Canadian Council for Animal Care. Approval for the study was obtained from the Animal Care Review Committee of the Hospital for Sick Children Research Institute.
Animal preparation. Four-to eight-day-old newborn SpragueDawley rats (Charles River, ON, Canada) were killed with an overdose of intraperitoneal pentobarbital sodium (50 mg/kg), and their lungs were removed immediately after death. Fetal rats of 20 -21 days of gestation (term ϭ 21 days) were delivered by hysterotomy (intramuscular pentobarbital sodium anesthesia, 20 mg/kg), and their lungs were removed immediately after delivery.
Organ bath studies. Fourth-generation left lung intralobar pulmonary artery ring segments (average diameter ϭ 100 m, length ϭ 2 mm) were dissected free and mounted in a wire myograph in isolation or with the bronchi attached.
Tissues were bathed in 5 ml of Krebs-Henseleit buffer (115 mM NaCl, 25 mM NaHCO 3, 1.38 mM NaHPO4, 2.51 mM KCl, 2.46 mM MgSO4, 1.91 mM CaCl2, and 5.56 mM dextrose) bubbled with air-6% CO2 (normoxia, organ bath PO2 ϭ 150 Torr) or nitrogen-6% CO2 (hypoxia, organ bath PO2 ϭ 40 Torr) and were maintained at 37°C. After 1 h of equilibration, the optimal resting tension of the tissue was determined by repeated stimulation with 128 mM KCl until maximum active tension was reached. All subsequent force measurements were obtained at optimal resting tension. The optimal resting tension was directly proportional to age, not affected by the presence of the attached bronchi, and varied between 1 and 2 mN. Isometric changes were digitized and recorded online (Myodaq; Danish Myo Technology, Aarhus, Denmark).
Pulmonary arterial muscle force generation was evaluated by stimulating with KCl (25-128 mM) and the thromboxane mimetic M), which have been shown by others to block the NO-cGMP and PI3-kinase pathways, respectively (18, 20) .
To evaluate the involvement of muscarinic receptors in methacholine-induced relaxation of pulmonary arteries with attached bronchi, the response was evaluated in the presence of selective inhibitors to the three muscarinic receptors: M 1 (pirenzepine, 10 Ϫ7 M), M2 (methoctramine tetrahydrochloride, 10 Ϫ6 M), and M3 (p-fluorohexahydro-sila-difenidol hydrochloride, 10 Ϫ6 M). The inhibitors' concentrations were based on reported evidence of effective blockade (3, 11, 15, 21, 23) . All inhibitors were added to the muscle bath 20 min before the experiments.
Data analysis. Data were evaluated by Student's t-test or two-way ANOVA, as indicated. Statistical significance was accepted if P Ͻ 0.05. All statistical analyses were performed with the Number Cruncher Statistical System (Kaysville, UT). Data are presented as means (SD).
RESULTS
In an attempt to induce the release of BrEpRF, we evaluated the response to methacholine in U-46619-stimulated pulmonary arteries alone and with the bronchi attached. The rationale for this approach was based on evidence that methacholine induces release of tracheal epithelium-derived relaxant factor in adult rats (4) . Figure 1A illustrates a representative muscle force generation tracing obtained from a pulmonary artery alone or with the bronchus attached. In the presence of the eNOS-specific blocker L-NIO (10 Ϫ4 M), methacholine induced relaxation solely in the pulmonary artery with the attached bronchus. Figure 1B illustrates the percentage relaxation measured in air-bubbled, U-46619-prestimulated newborn pulmonary artery either alone (n ϭ 4) or with bronchi attached (n ϭ 16). As shown, the methacholine-relaxant response of the newborn pulmonary artery is completely suppressed in the presence of the specific eNOS inhibitor L-NIO. In contrast, pulmonary arteries with the bronchi attached and in the presence of L-NIO exhibited significant muscle relaxant response to methacholine. The methacholine-induced relaxation response of pulmonary arteries with attached bronchi was reduced, but not statistically significantly lower, compared with the pulmonary artery alone (Fig. 1B) . Methacholine-induced relaxation of pulmonary arteries with attached bronchi was almost completely suppressed ( Fig. 2) in the presence of the soluble guanylate cyclase inhibitor ODQ (10 Ϫ5 M). The methacholine response was also significantly (P Ͻ 0.01) reduced in the presence of the PI3-kinase inhibitor wortmannin (10 Ϫ7 M) and the nonspecific muscarinic receptor inhibitor atropine (10 Ϫ5 M). All these measurements were obtained in the presence of L-NIO.
To identify the muscarinic receptor mediating methacholineinduced relaxation, we measured the response in the presence of increasing concentrations of M 1 -, M 2 -, and M 3 -selective muscarinic receptor blockers. Comparing the three inhibitors, we found the relaxation response to be significantly reduced at lower concentrations of the M 2 blocker (Fig. 3) . The ϪlogIC 50 (M) for the M 2 -selective muscarinic receptor blocker was 9.1 Ϯ 0.5 and significantly lower (P Ͻ 0.01) than that of the M 1 (7.7 Ϯ 0.5)-and M 3 (7.6 Ϯ 0.6)-selective muscarinic receptor blockers. These data suggest that M 2 is the muscarinic receptor primarily responsible for methacholine-induced relaxation.
As shown in Fig. 4A , and in keeping with our previously reported data (2), newborn pulmonary arteries with bronchi attached generated significantly (P Ͻ 0.01) less force than arteries alone when stimulated with U-46619 under normoxic conditions. Under hypoxic conditions, the U-46619 dose response for arteries without and with the attached bronchus was no longer different (Fig. 4A) . The hypoxia effect on force generation was only observed in the pulmonary arteries with attached bronchi. As evident from Fig. 4A , in response to U-46619 (10 Ϫ6 M), there was no significant effect of hypoxia on pulmonary arteries alone [force ϭ 2.4 (0.6) on air and 2.3 (0.7) mN/mm 2 under hypoxia]. In contrast, in response to the same molar concentration of U-46619, the force of pulmonary artery with attached bronchi significantly increased from 1.8 (0.6) on air to 2.7 (0.4) under hypoxic conditions (P Ͻ 0.01). Methacholine-induced relaxation of U-46619-prestimulated newborn pulmonary arteries with attached bronchi was significantly reduced (P Ͻ 0.01) under hypoxic conditions (Fig. 4B ).
To exclude a direct effect of hypoxia on the NO-mediated smooth muscle relaxant response as an explanation for the above findings, we also evaluated the pulmonary artery response to endothelium-dependent (ACh) and -independent (SNP) agonists. We found that the presence of an attached bronchus did not alter the pulmonary artery muscle response to either relaxant agonist (Fig. 5) , suggesting that the pulmonary arterial muscle NO-mediated relaxation is not acutely dependent on the O 2 tension, at least within the range tested.
Finally, we evaluated fetal rat pulmonary arteries alone and with attached bronchi under both normoxic and hypoxic conditions. The BrEpRF was not active in fetal tissue under normoxic conditions as evidenced by the similar dose response to KCl for the pulmonary arteries alone and with bronchi attached (Fig. 6, top) . Under hypoxic conditions, however, the pulmonary artery with attached bronchi generated a significantly greater (P Ͻ 0.01) force compared with the pulmonary artery alone (Fig. 6, bottom) . In addition, the methacholineinduced relaxant response of air-bubbled U-46619-prestimulated fetal pulmonary arteries with attached bronchi was negligible [0.3 (0.7) % relaxation]. In these arteries with attached bronchi, no significant difference in the U-46619-induced (10 Ϫ6 M) force was observed when studied under air [1.7 (0.5)] and hypoxic [1.5 (0.4)] conditions.
DISCUSSION
We have previously reported that in the newborn rat, the presence of an attached bronchus significantly reduces the thromboxane analog and KCl-stimulated pulmonary artery force generation when studied in air-bubbled Krebs-Henseleit solution (2) . This effect is dependent on the presence of an intact bronchial epithelium, but not pulmonary artery endothelium, and appears to be mediated by neuronal NOS and PI3-kinase (2) . These data suggest that under basal (nonstimulated) normoxic conditions, the newborn rat's bronchi are continuously producing a BrEpRF. An airway epithelium-derived factor capable of relaxing canine bronchial smooth muscle was first reported by Flavahan et al. (5) . It was subsequently shown to be present in the tracheal epithelium on the basis of the observation that methacholine-or histamine-stimulated tracheal tissue was able to relax endothelium-denuded adult rat aorta smooth muscle (4) . In this study, we sought to determine whether BrEpRF release and/or activity could also be stimulated pharmacologically, in a similar fashion. We found that methacholine stimulation of newborn pulmonary arteries with bronchi attached induced a relaxant response similar in magnitude to the one observed in these arteries when exposed to the NO donor SNP.
Methacholine is a muscarinic agonist similar to ACh. It induces contraction of airway smooth muscle, likely via stimulation of M 1 receptors (21) . Similar to ACh, methacholine can also relax the adult rat pulmonary arteries via an endotheliumdependent muscarinic receptor of either the M 1 (23) or M 3 type (10) . In this study, we showed that the methacholine-relaxant response of the newborn pulmonary artery is mediated via eNOS and is completely suppressed in the presence of the specific eNOS inhibitor L-NIO. In contrast, pulmonary arteries with the bronchi attached exhibited a significant muscle-relaxant response to methacholine in the presence of L-NIO. This suggests that in preparations with an attached bronchus, methacholine is able to induce pulmonary artery muscle relaxation via an eNOS-independent mechanism, likely modulated by BrEpRF release and/or activation. The methacholine-induced relaxation of the newborn pulmonary artery with attached bronchi is mediated via NO, given its dependence on the soluble guanylate cyclase, and involves the PI3-kinase pathway. Last, in contrast to its dual effect of epithelium-dependent relaxation and smooth muscle force generation on the airway, methacholine only induces endothelium-dependent relaxation in pulmonary arteries. Thus the possibility that bronchial smooth muscle contraction influences the attached pulmonary arterial relaxation potential cannot be excluded in the present study and deserves further investigation.
Our finding that the same downstream pathways were stimulated in pulmonary arteries by methacholine as by bronchial epithelium alone suggests that muscarinic receptors are involved in the release and/or activation of BrEpRF. Muscarinic cholinergic receptors are divided into four major subtypes (M 1 to M 4 ) according to their pharmacological properties. In the rat lung, all receptor subtypes appear to be prevalent except for M 4 (21) . In an attempt to identify the muscarinic receptor involved in methacholine-induced relaxation, we constructed dose-response curves for inhibitors with moderate selectivity for M 1 , M 2 , and M 3 receptors. Given the nonavailability of highly specific muscarinic receptor inhibitors (at high concentrations all receptors are inhibited with any of the blockers), we reasoned that this approach would enable us to identify the receptor most likely to mediate the methacholine-induced relaxant response. Methoctramine tetrahydrochloride, an M 2 receptor-selective inhibitor, significantly reduced the methacholine-induced relaxation at a lower molar concentration and exhibited a significantly lower ϪlogIC 50 compared with the M 1 -and M 3 -selective inhibitors, suggesting that M 2 receptors modulate the methacholine-induced muscle relaxation.
In this study, we demonstrated that under hypoxic conditions (buffer PO 2 ϭ40 Torr), the presence of attached bronchi altered neither the newborn pulmonary arterial muscle force generation nor the methacholine-induced relaxation, suggesting that the BrEpRF release and/or activity was suppressed by hypoxia. In addition, we showed that BrEpRF is not active in fetal vessels, even under normoxic conditions (buffer PO 2 ϭ 150 Torr).
The mechanisms accounting for the dependence of BrEpRF release and/or activity on O 2 tension in the rat lung are not clear from the present data. In sheep, the pulmonary arterial response to histamine is O 2 and age dependent (6) . Chronic (19) , but not acute, hypoxia has been shown to alter the hypoxic pulmonary vasoconstriction response. Hypoxia has also been shown to induce, in fetal pulmonary vascular smooth muscle, the production of reactive oxygen species and NO, the combination of which may result in the formation of peroxynitrite anion (14) . We have recently shown that in contrast to the adult, peroxynitrite anion induces significant pulmonary arterial contraction of newborn vessels and the formation of 8-isoprostane, another potent pulmonary vasoconstrictor (1). The possibility that peroxynitrite anion and/or 8-isoprostane formation, together with suppression of BrEpRF, are major contributors to hypoxic vasoconstriction in the newborn is a focus of our ongoing studies.
The O 2 dependence of the methacholine-induced relaxant response is likely to be related to its effect on BrEpRF release and/or the signal transduction pathway upstream from the NO release. This conclusion is based on the fact that the endothelium-derived (ACh) and donor-dependent, NO-mediated pulmonary artery muscle relaxation was not affected under the hypoxic conditions utilized in our experiments. This is in contrast to the observed abrogation of the endothelium-dependent relaxation in the newborn pulmonary artery of the pig (22) and newborn rat (unpublished observations) subjected to chronic hypoxia. Last, the methodology employed in this study to induce in vitro "hypoxia" deserves further comment. The buffer PO 2 under the experimental condition employed in this study is significantly higher than the pulmonary arterial blood PO 2 in vivo (40 Torr), yet the vessel's tissue PO 2 levels are likely similar. This conclusion is based on the fact that in vitro tissue oxygenation depends on O 2 diffusion across the vessel wall as opposed to the vasa vasorum blood perfusion-dependent O 2 delivery in vivo.
It is of interest that the BrEpRF appears to be either not present or not active during fetal life. As shown by our data in this study, this likely relates to the relatively hypoxic environment of the fetus (Pa O 2 ϭ 22 Torr in late gestation). Similar to our observation of the BrEpRF, expression of the airway epithelial sodium channel is PO 2 sensitive and upregulated immediately after birth (13) . There is also evidence that the cGMP-PKG pathway in fetal pulmonary vessels is upregulated following O 2 exposure, suggesting that it is PO 2 regulated (14) . In contrast to the newborn, hypoxia increased the KCl-induced, but not the U-46619-induced, force generation of pulmonary arteries with attached bronchi. Such distinct effect may be related to the mechanisms by which U-46619 causes contraction. Agonist-dependent differences in intracellular Ca 2ϩ release, or hypoxia-mediated Ca 2ϩ sensitization of the contractile apparatus (17) , may be developmentally regulated through pathways on which BrEpRF exerts its effects. Whether the BrEpRF is acutely regulated by changes in gene expression, release of vasoactive molecules, or as is likely, both, remains to be elucidated.
In summary, we have shown that the bronchial modulation of basal pulmonary arterial muscle tone under normoxic con- ditions in the newborn is suppressed by hypoxia and is not functional during late fetal life in the rat. These results suggest that the BrEpRF is involved in postnatal adaptation of the pulmonary circulation and that its suppression contributes to hypoxic pulmonary vasoconstriction in the newborn period.
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